2022
DOI: 10.2169/internalmedicine.8564-21
|View full text |Cite
|
Sign up to set email alerts
|

Erdheim-Chester Disease Involving the Central Nervous System with Latent Toxoplasmosis

Abstract: Erdheim-Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis characterized by the infiltration of foamy histiocytes into multiple organs. We herein report a case of ECD with central nervous system (CNS) involvement in a 63-year-old man who also presented a positive result for Toxoplasma gondii nested polymerase chain reaction testing of cerebrospinal fluid. Since anti-Toxoplasma treatment proved completely ineffective, we presumed latent infection of the CNS with T. gondii. This case suggests the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 27 publications
0
1
0
Order By: Relevance
“…ECD is a non-Langerhan histocyte neoplasm first described in 1930 by Jakob Erdheim and William Chester. [ 3 , 4 ] The World Health Organization classified ECD as a distinct entity in 2016, separate from disseminated juvenile xanthogranoloma, characterized by CD68-positive, CD1a-negative foamy histocytes infiltrating into tissue which can occur in multiple organs. [ 3 , 5 , 6 ] It is associated with mutations in the mitogen-activating protein kinase cell signaling pathway involving RAS-RAF-MEK-ERK, with patients in 1 case series of neurologic ECD found harboring mutations in BRAF (18/30 patients), MAP2K1 (5/30 patients), RAS isoforms (2/30 patients), or fusions of BRAF and ALK (2/30 patients).…”
Section: Discussionmentioning
confidence: 99%
“…ECD is a non-Langerhan histocyte neoplasm first described in 1930 by Jakob Erdheim and William Chester. [ 3 , 4 ] The World Health Organization classified ECD as a distinct entity in 2016, separate from disseminated juvenile xanthogranoloma, characterized by CD68-positive, CD1a-negative foamy histocytes infiltrating into tissue which can occur in multiple organs. [ 3 , 5 , 6 ] It is associated with mutations in the mitogen-activating protein kinase cell signaling pathway involving RAS-RAF-MEK-ERK, with patients in 1 case series of neurologic ECD found harboring mutations in BRAF (18/30 patients), MAP2K1 (5/30 patients), RAS isoforms (2/30 patients), or fusions of BRAF and ALK (2/30 patients).…”
Section: Discussionmentioning
confidence: 99%